Skip to main content

Strategies to identify and mitigate risks for first-in-human and early clinical trials with IMPs

EMA’s guidance non-clinical and clinical issues to consider prior to the first administration of an investigational medicinal product in humans. It also addresses the design and conduct of early clinical trials, including trials with integrated protocols.

 

EMA logo

Strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products - Scientific guideline

Achou o conteúdo desta página útil? Se não, pode deixar-nos uma mensagem para que possamos melhorar Envie-nos as suas ideias